Tetiana Taran
Novartis (Switzerland)(CH)Lublin Oncology Center(PL)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, PI3K/AKT/mTOR signaling in cancer, HER2/EGFR in Cancer Research, Cancer Genomics and Diagnostics
Most-Cited Works
- → Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia(2018)5,468 cited
- → ESR1 ligand-binding domain mutations in hormone-resistant breast cancer(2013)1,235 cited
- → Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3(2018)1,086 cited
- → Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer(2019)1,001 cited
- → Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer(2019)821 cited
- → Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis(2013)514 cited
- → Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial(2014)490 cited
- → Ribociclib plus Endocrine Therapy in Early Breast Cancer(2024)313 cited
- → Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial(2015)301 cited